State AGs letter urging availability of coronavirus drug shot down by HHS
Gilead’s remdesivir reduces coronavirus mortality risk: Study
Family emergency medicine physician Dr. Janette Nesheiwat applauds President Trump for securing 100 percent of remdesivir for the month of July and 90 percent for August and September since there’s now a shortage of the drug.
The Department of Health and Human Services pushed back against a letter signed by more than 30 state attorneys general concerned that the federal government is not doing enough to get Gilead Sciences' coronavirus treatment remdesivir to the American people.
Continue Reading Below
The letter's request for the government to use the Bayh-Dole Act to grant march-in rights to states to allow other firms to manufacture remdesivir is a non-starter, an HHS spokesperson told FOX Business. The spokesperson said march-in rights only apply to products with intellectual property that was funded by the federal government, meaning all patents underlying the product were conceived or reduced to practice with federal funds.
COVID-19 DRUG REMDESIVIR TO COST $3,120 FOR TYPICAL PATIENT ON PRIVATE INSURANCE
Louisiana Attorney General Jeff Landry and California Attorney General Xavier Becerra, a Republican and a Democrat, led the charge Tuesday to "urge the federal government to exercise its rights under the Bayh-Dole Act, which will allow the National Institutes of Health (NIH) and the FDA to ensure that Americans can afford and access a sufficient supply of remdesivir during this pandemic."
"[W]e think it is clear that Gilead has not established a reasonable price, nor has it met the health and safety needs of the public given the COVID-19 pandemic," the attorneys general wrote. "We urge the federal government to use its march-in rights to help increase the supply of this drug and lower the price so it is accessible to our state residents."